1 week Ago By Defense World Staff
Prudential Financial Inc. acquired a new stake in shares of MaxCyte, Inc. ( NASDAQ:MXCT – Free Report ) during the 4th quarter, according to its most recent disclosure with the SEC.
The fund acquired 15,630 shares of the company’s stock, valued at approximately $65,000. Other hedge funds have also recently modified their holdings of the company. Catalyst Funds Management Pty Ltd bought a new stake in MaxCyte during the 4th quarter valued at about $74,000.
Verition Fund Management LLC raised its holdings in MaxCyte by 39.5% in the 3rd quarter. Verition Fund Management LLC now owns 21,335 shares of the company’s stock worth $83,000 after purchasing an additional 6,045 shares during the period.
China Universal Asset Management Co. Ltd. raised its stake in MaxCyte by 10.
7% during the 4th quarter. China Universal Asset Management Co. Ltd.
now owns 22,366 shares of the company’s stock worth $93,000 after acquiring an additional 2,154 shares during the period. SG Americas Securities LLC boosted its holdings in MaxCyte by 25.9% in the 4th quarter.
SG Americas Securities LLC now owns 47,805 shares of the company’s stock worth $199,000 after buying an additional 9,836 shares during the period. Finally, Franklin Resources Inc. bought a new position in MaxCyte in the 3rd quarter worth approximately $260,000.
Institutional investors own 68.81% of the company’s stock. Analyst Ratings Changes Several brokerages have recently issued reports on MXCT.
BTIG Research set a $6.00 price objective on MaxCyte and gave the stock a “buy” rating in a report on Wednesday, March 12th. Stifel Nicolaus lowered their target price on shares of MaxCyte from $11.
00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, March 12th. MaxCyte Trading Up 10.
3 % Shares of NASDAQ:MXCT opened at $2.58 on Friday. MaxCyte, Inc.
has a 12-month low of $2.21 and a 12-month high of $5.26.
The company has a market capitalization of $274.29 million, a PE ratio of -7.59 and a beta of 1.
39. The business’s fifty day simple moving average is $3.34 and its 200-day simple moving average is $3.
77. MaxCyte Company Profile ( Free Report ) MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Further Reading Five stocks we like better than MaxCyte How Investors Can Identify and Successfully Trade Gap-Down Stocks JPMorgan is a Buy, if You Can Handle The Volatility Why Invest in High-Yield Dividend Stocks? United States Steel’s Crash: An Unmissable Buying Opportunity Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness Rocket Lab Stock: Weathering the Storm, Time for a Comeback? Want to see what other hedge funds are holding MXCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MaxCyte, Inc. ( NASDAQ:MXCT – Free Report ).
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter ..
